
Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally.

- Data collection can be very challenging for patients with visual impairment, but the patient- and site-centric research approach that we've seen growing for several years allows clinical trials to be better adapted to patient needs.

Measuring patients' perception of their symptoms and their quality of life using efficient ePRO solutions is essential in ophthalmology clinical research.


Kayentis offers tailored decentralized solutions with qualitative ePROs and extensive experience in ophthalmology to ensure the success of ophthalmology clinical trials by:

securing ePRO data collection with adapted electronic devices and multiple data collection modes,
understanding and integrating patients' specificities and preferences,
and anticipating unscheduled visits with strong product capabilities and processes


Learn more in the case study:

CASE STUDY - OPHTHALMOLOGY

Kayentis offers a wealth of experience in conducting clinical trials for ophthalmic conditions



Kayentis offers tailored decentralized solutions with qualitative ePROs (PRO VFQ 25 / NEI VFQ28R / NAVQ / drop comfort assessment), and extensive experience in ophthalmology (eg, Central/branch Retinal Vein Occlusion; Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema; Diabetic Retinopathy; Presbyopia; Chronic Ocular Pain; Dry Eye Disease).

 **kayentis**
Global eCOA & DCT provider

[Download the case study](#)
[Contact us for more information](#)

Key Words:

- eCOA

- ePRO
- eDiary
- ophthalmology
- clinical trial

[Learn more:](#)



Rethinking pediatric clinical trials: guidelines from pediatric experts

2 April 2024

In this last episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



Overcoming challenges in long-lasting pediatric clinical trials – Insights from site experts

26 March 2024

In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



Tackling the specificities of NASH/MASH clinical trials

26 March 2024

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating

[Read More »](#)



Mastering pediatric asthma clinical trials

19 March 2024

Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of

[Read More »](#)



The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

14 March 2024

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally

[Read More »](#)



How DCTs Can Help Pediatric Clinical Research – Insights From Site Experts

12 March 2024

In this second episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)